Details for Patent: 6,451,991
✉ Email this page to a colleague
Summary for Patent: 6,451,991
Title: | Sugar-modified gapped oligonucleotides |
Abstract: | Oligonucleotides are provided which have increased nuclease resistance, substituent groups for increasing binding affinity to complementary nucleic acid strand, and subsequences of 2'-deoxy-erythro-pentofuranosyl nucleosides that activate RNase H. Such oligonucleotides are useful for diagnostics and other research purposes, for modulating the expression of a protein in organisms, and for the diagnosis, detection and treatment of other conditions susceptible to ooligonucleotide therapeutics. |
Inventor(s): | Martin; Pierre (Rheinfelden, CH), Altmann; Karl-Heinz (Reinach, CH), Cook; Phillip Dan (Vista, CA), Monia; Brett P. (Carlsbad, CA) |
Assignee: | ISIS Pharmaceuticals, Inc. (Carlsbad, CA) Novartis AG (CH) |
Application Number: | 08/802,331 |
Patent Claim Types: see list of patent claims | Compound; |
Drugs Protected by US Patent 6,451,991
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 6,451,991
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Austria | 267207 | ⤷ Sign Up | |||
Australia | 1955297 | ⤷ Sign Up | |||
Australia | 725262 | ⤷ Sign Up | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |